ICH Q1/Q5C EWG Work Plan July 20, 2023

Topic Adoption date: June 2022

Rapporteur: Ms. Megan McMahon, PhRMA

Regulatory Chair: Dr. Ashutosh Rao, FDA, United States

Last Face-to-Face Meeting: Vancouver, Canada, June 2023

1. Key milestones

1.a. Current status of key milestones

Past		
completion date	Milestone	
Nov. 2022	Concept paper endorsement	
Nov. 2022	Business plan endorsement	
Nov. 2022	Establishment of EWG	

1.b. Future anticipated key milestones

Expected future completion date	Milestone	
Dec. 2024	Step 1 and 2a/b Sign-off of Q1/Q5C draft Technical Document	
Dec. 2025	 Step 3 and 4 Sign-off and Adoption of the Q1/Q5C Guideline Completion of Training Materials 	

2. Timeline for specific tasks

Beginning date	End date	Task / Activity	Details
Jun. 2023	Jul. 2023	Define workstreams for next 6 months	Identify/align on workstreams/subteams for next unit of work, which includes addressing comments received, completing content authoring, aligning terminology with other ICH guidelines and incorporating examples

Jul. 2023	Oct. 2023	Comment resolution	Complete comment resolution for early draft
Jul. 2023	Oct. 2023	Section Drafting	Complete drafting additional sections (e.g. bracketing/matrixing section)
Oct. 2023	Nov. 2023	Comprehensive EWG review	Complete EWG comprehensive review of content, identify any remaining gaps, define actions to Step 1 Draft
Oct. 2023	Dec. 2023	Alignment with other ICH content	Alignment with active EWGs and guidelines on common and complementary content
Oct. 2023	Jan. 2024	Glossary and terminology	Complete glossary and harmonisation of terminology with other ICH documents
Oct. 2023	Feb. 2024	Complete examples	Incorporation of examples into Step 1
Mar. 2024	May. 2024	Collect constituency feedback	Issue Step 1 DRAFT for constituency review (2-month review planned after draft is shared)